HK Stock MarketDetailed Quotes

06600 SCICLONE PHARMA

Watchlist
  • 17.960
  • -0.080-0.44%
Trading Apr 16 14:27 CST
11.27BMarket Cap9.11P/E (TTM)

SCICLONE PHARMA Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

All
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2023
(Q6)Jun 30, 2023
(FY)Dec 31, 2022
(Q6)Jun 30, 2022
(FY)Dec 31, 2021
(Q6)Jun 30, 2021
(FY)Dec 31, 2020
(Q9)Sep 30, 2020
(Q6)Jun 30, 2020
(FY)Dec 31, 2019
Turnover
14.76%3.16B
8.70%1.6B
9.18%2.75B
10.80%1.48B
31.27%2.52B
14.67%1.33B
12.32%1.92B
22.73%1.58B
33.07%1.16B
21.24%1.71B
Operating income
14.76%3.16B
8.70%1.6B
9.18%2.75B
10.80%1.48B
31.27%2.52B
14.67%1.33B
12.32%1.92B
22.73%1.58B
33.07%1.16B
21.24%1.71B
Cost of sales
-17.70%-799.41M
-19.85%-408.62M
-16.01%-679.2M
-19.47%-340.94M
-36.76%-585.47M
-21.34%-285.38M
-8.89%-428.11M
-18.21%-346.06M
-16.00%-235.18M
-29.75%-393.14M
Operating expenses
-17.70%-799.41M
-19.85%-408.62M
-16.01%-679.2M
-19.47%-340.94M
-36.76%-585.47M
-21.34%-285.38M
-8.89%-428.11M
-18.21%-346.06M
-16.00%-235.18M
-29.75%-393.14M
Gross profit
13.80%2.36B
5.34%1.19B
7.11%2.07B
8.43%1.13B
29.69%1.93B
12.98%1.05B
13.35%1.49B
24.06%1.24B
38.24%925.8M
18.90%1.31B
Selling expenses
-13.55%-712.81M
-16.82%-326.55M
-8.39%-627.75M
-11.25%-279.54M
-26.90%-579.16M
-47.85%-251.28M
0.86%-456.39M
5.56%-298.43M
19.91%-169.96M
-18.32%-460.33M
Administrative expenses
-14.35%-257.3M
34.19%-62.7M
-8.98%-225M
-8.03%-95.27M
4.52%-206.46M
-26.77%-88.19M
-82.64%-216.22M
-58.87%-146.24M
-13.06%-69.57M
17.50%-118.39M
Research and development expenses
-37.80%-170.68M
-45.35%-72.73M
7.83%-123.86M
-26.65%-50.03M
-78.19%-134.39M
-31.84%-39.51M
13.99%-75.42M
17.94%-48.72M
5.49%-29.97M
-13.20%-87.69M
Special items of operating profit
92.80%-10.31M
68.83%-38.06M
-417.60%-143.27M
-487.53%-122.11M
-51.23%45.11M
536.73%31.51M
5,448.65%92.5M
269.69%18.29M
-195.80%-7.22M
210.11%1.67M
Operating profit
26.77%1.21B
18.31%694.68M
-10.16%950.6M
-15.93%587.18M
26.73%1.06B
7.61%698.47M
28.41%834.92M
46.79%763.01M
74.58%649.09M
31.52%650.19M
Financing income
95.41%70.48M
320.04%33.54M
353.24%36.07M
154.62%7.99M
-30.67%7.96M
-53.39%3.14M
-5.69%11.48M
11.91%9.19M
111.37%6.73M
357.73%12.17M
Financing cost
-24.90%-58.19M
-79.39%-29.98M
-15.93%-46.59M
25.08%-16.71M
-35.82%-40.19M
-687.78%-22.31M
-2,388.81%-29.59M
-1,478.66%-17.38M
-172.05%-2.83M
31.75%-1.19M
Earning before tax
29.50%1.22B
20.71%698.24M
-8.36%940.08M
-14.85%578.45M
25.60%1.03B
4.03%679.3M
23.54%816.81M
43.25%754.82M
74.62%652.99M
33.50%661.17M
Tax
-12.71%-95.5M
-47.12%-68.05M
17.35%-84.73M
18.27%-46.26M
-62.42%-102.51M
-1.29%-56.6M
-35.53%-63.11M
-63.70%-65.07M
-111.53%-55.88M
-216.98%-46.57M
After-tax profit from continuing operations
31.16%1.12B
18.41%630.18M
-7.37%855.36M
-14.53%532.2M
22.51%923.36M
4.29%622.7M
22.63%753.7M
41.58%689.76M
71.81%597.11M
14.86%614.6M
Earning after tax
31.16%1.12B
18.41%630.18M
-7.37%855.36M
-14.53%532.2M
22.51%923.36M
4.29%622.7M
22.63%753.7M
41.58%689.76M
71.81%597.11M
14.86%614.6M
Profit attributable to shareholders
31.16%1.12B
18.41%630.18M
-7.37%855.36M
-14.53%532.2M
22.51%923.36M
4.29%622.7M
22.63%753.7M
41.58%689.76M
71.81%597.11M
14.86%614.6M
Basic earnings per share
44.09%1.83
26.58%1
-10.56%1.27
-20.20%0.79
2.90%1.42
-10.00%0.99
22.12%1.38
40.00%1.26
71.88%1.1
14.14%1.13
Diluted earnings per share
42.15%1.72
28.00%0.96
-9.02%1.21
-18.48%0.75
-1.48%1.33
-16.36%0.92
19.47%1.35
38.89%1.25
71.88%1.1
14.14%1.13
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
IAS
IAS
IAS
IAS
IAS
IAS
IAS
IAS
IAS
IAS
Audit Opinions
Unqualified Opinion
--
Unqualified Opinion
--
Unqualified Opinion
--
Unqualified Opinion
--
--
Unqualified Opinion
Auditor
PricewaterhouseCoopers
--
PricewaterhouseCoopers
--
PricewaterhouseCoopers
--
PricewaterhouseCoopers
--
--
PricewaterhouseCoopers
(FY)Dec 31, 2023(Q6)Jun 30, 2023(FY)Dec 31, 2022(Q6)Jun 30, 2022(FY)Dec 31, 2021(Q6)Jun 30, 2021(FY)Dec 31, 2020(Q9)Sep 30, 2020(Q6)Jun 30, 2020(FY)Dec 31, 2019
Turnover 14.76%3.16B8.70%1.6B9.18%2.75B10.80%1.48B31.27%2.52B14.67%1.33B12.32%1.92B22.73%1.58B33.07%1.16B21.24%1.71B
Operating income 14.76%3.16B8.70%1.6B9.18%2.75B10.80%1.48B31.27%2.52B14.67%1.33B12.32%1.92B22.73%1.58B33.07%1.16B21.24%1.71B
Cost of sales -17.70%-799.41M-19.85%-408.62M-16.01%-679.2M-19.47%-340.94M-36.76%-585.47M-21.34%-285.38M-8.89%-428.11M-18.21%-346.06M-16.00%-235.18M-29.75%-393.14M
Operating expenses -17.70%-799.41M-19.85%-408.62M-16.01%-679.2M-19.47%-340.94M-36.76%-585.47M-21.34%-285.38M-8.89%-428.11M-18.21%-346.06M-16.00%-235.18M-29.75%-393.14M
Gross profit 13.80%2.36B5.34%1.19B7.11%2.07B8.43%1.13B29.69%1.93B12.98%1.05B13.35%1.49B24.06%1.24B38.24%925.8M18.90%1.31B
Selling expenses -13.55%-712.81M-16.82%-326.55M-8.39%-627.75M-11.25%-279.54M-26.90%-579.16M-47.85%-251.28M0.86%-456.39M5.56%-298.43M19.91%-169.96M-18.32%-460.33M
Administrative expenses -14.35%-257.3M34.19%-62.7M-8.98%-225M-8.03%-95.27M4.52%-206.46M-26.77%-88.19M-82.64%-216.22M-58.87%-146.24M-13.06%-69.57M17.50%-118.39M
Research and development expenses -37.80%-170.68M-45.35%-72.73M7.83%-123.86M-26.65%-50.03M-78.19%-134.39M-31.84%-39.51M13.99%-75.42M17.94%-48.72M5.49%-29.97M-13.20%-87.69M
Special items of operating profit 92.80%-10.31M68.83%-38.06M-417.60%-143.27M-487.53%-122.11M-51.23%45.11M536.73%31.51M5,448.65%92.5M269.69%18.29M-195.80%-7.22M210.11%1.67M
Operating profit 26.77%1.21B18.31%694.68M-10.16%950.6M-15.93%587.18M26.73%1.06B7.61%698.47M28.41%834.92M46.79%763.01M74.58%649.09M31.52%650.19M
Financing income 95.41%70.48M320.04%33.54M353.24%36.07M154.62%7.99M-30.67%7.96M-53.39%3.14M-5.69%11.48M11.91%9.19M111.37%6.73M357.73%12.17M
Financing cost -24.90%-58.19M-79.39%-29.98M-15.93%-46.59M25.08%-16.71M-35.82%-40.19M-687.78%-22.31M-2,388.81%-29.59M-1,478.66%-17.38M-172.05%-2.83M31.75%-1.19M
Earning before tax 29.50%1.22B20.71%698.24M-8.36%940.08M-14.85%578.45M25.60%1.03B4.03%679.3M23.54%816.81M43.25%754.82M74.62%652.99M33.50%661.17M
Tax -12.71%-95.5M-47.12%-68.05M17.35%-84.73M18.27%-46.26M-62.42%-102.51M-1.29%-56.6M-35.53%-63.11M-63.70%-65.07M-111.53%-55.88M-216.98%-46.57M
After-tax profit from continuing operations 31.16%1.12B18.41%630.18M-7.37%855.36M-14.53%532.2M22.51%923.36M4.29%622.7M22.63%753.7M41.58%689.76M71.81%597.11M14.86%614.6M
Earning after tax 31.16%1.12B18.41%630.18M-7.37%855.36M-14.53%532.2M22.51%923.36M4.29%622.7M22.63%753.7M41.58%689.76M71.81%597.11M14.86%614.6M
Profit attributable to shareholders 31.16%1.12B18.41%630.18M-7.37%855.36M-14.53%532.2M22.51%923.36M4.29%622.7M22.63%753.7M41.58%689.76M71.81%597.11M14.86%614.6M
Basic earnings per share 44.09%1.8326.58%1-10.56%1.27-20.20%0.792.90%1.42-10.00%0.9922.12%1.3840.00%1.2671.88%1.114.14%1.13
Diluted earnings per share 42.15%1.7228.00%0.96-9.02%1.21-18.48%0.75-1.48%1.33-16.36%0.9219.47%1.3538.89%1.2571.88%1.114.14%1.13
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards IASIASIASIASIASIASIASIASIASIAS
Audit Opinions Unqualified Opinion--Unqualified Opinion--Unqualified Opinion--Unqualified Opinion----Unqualified Opinion
Auditor PricewaterhouseCoopers--PricewaterhouseCoopers--PricewaterhouseCoopers--PricewaterhouseCoopers----PricewaterhouseCoopers

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg